Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 10374

Next Previous
Drug Profile

HS 10374

Alternative Names: HS-10374

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Changzhou Hengbang Pharmaceutical; Jiangsu Hansoh Pharmaceutical
  • Class Antipsoriatics
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis; Psoriatic arthritis

Most Recent Events

  • 09 Apr 2025 Hansoh BioMedical plans a phase II trial for Psoriasis in China, in April 2025 (PO, Tablet) (NCT06926582)
  • 04 Nov 2024 Hansoh BioMedical R&D Company plans a phase III trial for Psoriasis in China in November 2024 (PO) (NCT06672393)
  • 26 Feb 2024 Phase-II clinical trials in Psoriatic arthritis in China (PO) (NCT06176508)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top